Skip to main content Accessibility help
×
Home

Effects of N-acetylcysteine on substance use in bipolar disorder: a randomised placebo-controlled clinical trial

  • Michelle Bernardo (a1), Seetal Dodd (a1), Clarissa S. Gama (a2), David L Copolov (a3) (a4), Olivia Dean (a1) (a3), Kristy Kohlmann (a1) (a3), Susan Jeavons (a3), Ian Schapkaitz (a3), Murray Anderson-Hunt (a3), Ashley I Bush (a3) and Michael Berk (a1) (a5) (a3)...

Abstract

Objective:

To evaluate the effect of N-acetylcysteine (NAC) on substance use in a double-blind, placebo-controlled trial of NAC in bipolar disorder. It is hypothesised that NAC will be superior to placebo for reducing scores on the Clinical Global Impressions scale for Substance Use (CGI-SU).

Methods:

Participants were randomised to 6-months of treatment with 2 g/day NAC (n = 38) or placebo (n = 37). Substance use was assessed at baseline using the Habits instrument. Change in substance use was assessed at regular study visits using the CGI-SU.

Results:

Amongst the 75 participants 78.7% drank alcohol (any frequency), 45.3% smoked tobacco and 92% consumer caffeine. Other substances were used by fewer than six participants. Caffeine use was significantly lower for NAC-treated participants compared with placebo at week 2 of treatment but not at other study visits.

Conclusion:

NAC appeared to have little effect on substance use in this population. A larger study on a substance using population will be necessary to determine if NAC may be a useful treatment for substance use.

Copyright

Corresponding author

Dr Seetal Dodd Department of Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, PO Box 281, Geelong 3220, Australia. Tel: +61 3 5226 7666; Fax: +61 3 5246 5165; E-mail: seetald@barwonhealth.org.au

References

Hide All
1.Berk, M, Dodd, S, Berk, L.The management of bipolar disorder in primary care: a review of existing and emerging therapies. Psychiatry Clin Neurosci 2005;59:229239.
2.Regier, DA, Farmer, ME, Rae, DSet al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:25112518.
3.Goldberg, JF, Garno, JL, Leon, AC, Kocsis, JH, Portera, L.A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry 1999;60:733740.
4.Dossing, M, Sonne, J.Drug-induced hepatic disorders. Incidence, management and avoidance. Drug Saf 1993;9:441449.
5.Cassidy, F, Ahearn, EP, Carroll, BJ.Substance abuse in bipolar disorder. Bipolar Disord 2001;3:181188.
6.Castro, AA, Moretti, M, Casagrande, TSet al. Neuropeptide S produces hyperlocomotion and prevents oxidative stress damage in the mouse brain: a comparative study with amphetamine and diazepam. Pharmacol Biochem Behav 2009;91:636642.
7.Reddy, RD, Yao, JK.Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 1996;55:3343.
8.Ozcan, ME, Gulec, M, Ozerol, E, Polat, R, Akyol, O.Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004;19:8995.
9.Machado-Vieira, R, Andreazza, AC, Viale, CIet al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007;421:3336.
10.Andreazza, AC, Cassini, C, Rosa, ARet al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007;41:523529.
11.Frey, BN, Andreazza, AC, Kunz, Met al. Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:283285.
12.Grignon, S, Chianetta, JM.Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:365369.
13.Gama, CS, Berk, M, Andreazza, AC, Kapczinski, F, Belmonte-de-Abreu, P.Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation. Rev Bras Psiquiatr 2008;30:337340.
14.Gama, CS, Salvador, M, Andreazza, AC, Kapczinski, F, Silva Belmonte-de-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:512515.
15.Gama, CS, Salvador, M, Andreazza, ACet al. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neurosci Lett 2008;433:270273.
16.Kalivas, PW, O’Brien, C.Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 2008;33:166180.
17.Stork, C, Renshaw, PF.Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005;10:900919.
18.Wozniak, B, Musialkiewicz, D, Wozniak, Aet al. Lack of changes in the concentration of thiobarbituric acid-reactive substances (TBARS) and in the activities of erythrocyte antioxidant enzymes in alcohol-dependent patients after detoxification. Med Sci Monit 2008;14:CR32CR36.
19.Baker, DA, McFarland, K, Lake, RWet al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neuroscience 2003;6:743749.
20.Moran, MM, McFarland, K, Melendez, RI, Kalivas, PW, Seamans, JK.Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci 2005;25:63896393.
21.McFarland, K, Lapish, CC, Kalivas, PW.Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 2003;23:35313537.
22.Madayag, A, Lobner, D, Kau, KSet al. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. J Neurosci 2007;27:1396813976.
23.Zhou, W, Kalivas, PW.N-acetylcysteine reduces extinction responding and induces enduring reductions in cue- and heroin-induced drug-seeking. Biol Psychiatry 2008;63:338340.
24.Grant, JE, Kim, SW, Odlaug, BL.N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007;62:652657.
25.Burgunder, JM, Varriale, A, Lauterburg, BH.Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 1989;36:127131.
26.Holdiness, MR.Clinical pharmokinetics of N-acetylcysteine. Clincal Pharmokinetics 1991;20:123134.
27.Dean, O, van den Buuse, M, Copolov, DL, Berk, M, Bush, AI.N-acetylcysteine treatment inhibits depletion of brain glutathione levels in rats: implications for schizophrenia. Int J Neuropsychopharmacol 2004;7:S262.
28.Andreassen, OA, Dedeoglu, A, Klivenyi, P, Beal, MF, Bush, AI.N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. NeuroReport 2000;11:24912493.
29.Louwerse, ES, Weverling, GJ, Bossuyt, PM, Meyjes, FE, De Jong, JM.Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995;52:559564.
30.Rothstein, JD, Bristol, LA, Hosler, B, Brown, RH Jr, Kuncl, RW.Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci U S A 1994;91:41554159.
31.Koppal, T, Drake, J, Butterfield, DA.In vivo modulation of rodent glutathione and its role in peroxynitrite-induced neocortical synaptosomal membrane protein damage. Biochimica et Biophysica Acta 1999;1453:407411.
32.Mayer, M, Noble, M.N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci U S A 1994;91:74967500.
33.Staal, FJ, Anderson, MT, Herzenberg, LA.Redox regulation of activation of NF-kappa B transcription factor complex: effects of N-acetylcysteine. Methods Enzymol 1995;252:168174.
34.Ferrari, G, Yan, CY, Greene, LA.N-acetylcysteine (D- and L-stereoisomers) prevents apoptotic death of neuronal cells. J Neurosci 1995;15:28572866.
35.Berk, M, Copolov, D, Dean, Oet al. N-acetyl cysteine as a glutathione precursor for schizophrenia–a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008;64:361368.
36.Berk, M, Copolov, DL, Dean, Oet al. N-acetyl cysteine for depressive symptoms in bipolar disorder–a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;64:468475.
37.Guy, W.ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch, 1976.

Keywords

Related content

Powered by UNSILO

Effects of N-acetylcysteine on substance use in bipolar disorder: a randomised placebo-controlled clinical trial

  • Michelle Bernardo (a1), Seetal Dodd (a1), Clarissa S. Gama (a2), David L Copolov (a3) (a4), Olivia Dean (a1) (a3), Kristy Kohlmann (a1) (a3), Susan Jeavons (a3), Ian Schapkaitz (a3), Murray Anderson-Hunt (a3), Ashley I Bush (a3) and Michael Berk (a1) (a5) (a3)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.